| | Ustekinumab | TNF inhibitorsa | Infliximab | Etanercept | Adalimumab | Non-biologic/MTXb | Non-biologic/non-MTXc | Alld |
|---|
Overall population |
N | 628 | 1413 | 258 | 481 | 674 | 98 | 208 | 2401 |
Patient-years | 2009 | 4101 | 756 | 1432 | 1913 | 366 | 694 | 7244 |
Duration of follow-up, years |
Mean ± SD | 5.0 ± 1.9 | 4.9 ± 2.2 | 4.7 ± 2.3 | 4.8 ± 2.3 | 5.0 ± 2.1 | 4.2 ± 2.2 | 3.7 ± 2.6 | 4.8 ± 2.2 |
Median | 5.16 | 5.16 | 4.70 | 5.16 | 5.35 | 4.32 | 3.50 | 5.11 |
Incident population |
N | 326 | 486 | 64 | 130 | 292 | 98 | 208 | 1163 |
Patient-years | 904 | 1082 | 125 | 291 | 665 | 366 | 694 | 3101 |
Duration of follow-up, years |
Mean ± SD | 5.4 ± 1.9 | 5.4 ± 2.0 | 5.3 ± 2.0 | 5.5 ± 2.0 | 5.4 ± 2.0 | 4.2 ± 2.2 | 3.7 ± 2.6 | 5.0 ± 2.2 |
Median | 5.71 | 5.61 | 5.67 | 5.64 | 5.59 | 4.32 | 3.50 | 5.40 |
Bionaive population |
N | 56 | 167 | 14 | 72 | 81 | 98 | 208 | 532 |
Patient-years | 144 | 419 | 35 | 180 | 204 | 366 | 694 | 1626 |
Duration of follow-up, years |
Mean ± SD | 4.4 ± 2.0 | 5.2 ± 2.0 | 4.6 ± 1.8 | 5.6 ± 2.2 | 4.8 ± 1.9 | 4.2 ± 2.2 | 3.7 ± 2.6 | 4.4 ± 2.3 |
Median | 4.66 | 5.52 | 4.39 | 6.17 | 5.14 | 4.32 | 3.50 | 4.70 |
- The biologic user cohort includes patients who are on the cohort defining biologic at entry or start the biologic after entry; previous use or current exposure is allowed for MTX, but not for other systemic immunomodulators
- MTX methotrexate; PsA, psoriatic arthritis; PSOLAR, Psoriasis Longitudinal Assessment and Registry; SD, standard deviation
- aTumor necrosis factor (TNF) inhibitors include infliximab, etanercept, and adalimumab
- bThe non-biologic/MTX cohort includes patients who are receiving MTX at entry or start methotrexate during the registry and haven’t been exposed to other systemic immunomodulators previously or concurrently
- cNon-biologic, non-MTX therapies may include, but are not limited to, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, oral corticosteroids, systemic retinoids, psoralen plus ultraviolet (UV), or UVB phototherapy. The non-biologic/non-MTX cohort includes patients who are receiving other systemic immunomodulators (including cyclosporine, tacrolimus, mycophenolate mofetil, other immunomodulators, and oral corticosteroids) at entry or start other immunomodulators after registry and who haven’t been exposed to MTX previously or concurrently; patients who receive only topical and/or phototherapy at/after registry entry are also in this cohort
- dIncludes “Other biologics” group (n = 54); data not shown
